ICU胃肠道出血风险患者的泮托拉唑预防治疗
这项欧洲多中心、平行组、盲法试验纳入因急性情况非计划入住ICU且有胃肠道出血风险的成人,随机接受每日静脉泮托拉唑40 mg或安慰剂。共纳入3298例患者,泮托拉唑组1645例,安慰剂组1653例。90天死亡率泮托拉唑组31.1% vs 安慰剂组30.4%(RR 1.02;95%CI 0.91-1.13;P=0.76)。ICU期间至少发生一项临床重要事件(临床重要胃肠道出血、肺炎、艰难梭菌感染或心肌缺血的复合终点)的比例分别为21.9% vs 22.6%(RR 0.96;95%CI 0.83-1.11)。临床重要胃肠道出血发生率泮托拉唑组2.5% vs 安慰剂组4.2%。结论认为两组90天死亡率和临床重要事件数相似。
要点
- 在有胃肠道出血风险的ICU成人中,每日静脉泮托拉唑40 mg与安慰剂相比,90天死亡率分别为31.1% vs 30.4%(RR 1.02;95%CI 0.91-1.13;P=0.76),无显著差异。
- ICU期间临床重要事件复合终点(临床重要胃肠道出血、肺炎、艰难梭菌感染或心肌缺血)发生率泮托拉唑组21.9% vs 安慰剂组22.6%(RR 0.96;95%CI 0.83-1.11),无显著差异。
- 临床重要胃肠道出血发生率泮托拉唑组2.5% vs 安慰剂组4.2%。
- 两组感染或严重不良反应的患者数及90天内无生命支持存活天数百分比相似。
适用人群与场景
- 因急性情况(非计划入院)入住ICU的成人,且有胃肠道出血风险。
处置流程与药物剂量
- 泮托拉唑40 mg静脉给药,每日一次,ICU住院期间使用。
研究设计与关键结果
- 研究类型:欧洲多中心、平行组、盲法试验;样本量3298例(泮托拉唑组1645例,安慰剂组1653例);主要终点数据可得3282例(99.5%)。
- 主要终点:90天死亡率泮托拉唑组31.1%(510例) vs 安慰剂组30.4%(499例),RR 1.02;95%CI 0.91-1.13;P=0.76。
- 关键次要终点:ICU期间至少一项临床重要事件(临床重要胃肠道出血、肺炎、艰难梭菌感染或心肌缺血的复合终点)发生率泮托拉唑组21.9% vs 安慰剂组22.6%,RR 0.96;95%CI 0.83-1.11。
- 临床重要胃肠道出血发生率泮托拉唑组2.5% vs 安慰剂组4.2%。
- 两组感染或严重不良反应的患者数及90天内无生命支持存活天数百分比相似。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于有胃肠道出血风险的ICU成人,每日静脉泮托拉唑40 mg与安慰剂相比,90天死亡率和临床重要事件复合终点相似。
指南或共识出处
- SUP-ICU试验;ClinicalTrials.gov注册号NCT02467621;由Innovation Fund Denmark等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear.
METHODS: In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization.
RESULTS: A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to pantoprazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal bleeding, as compared with 4.2% in the placebo group. The number of patients with infections or serious adverse reactions and the percentage of days alive without life support within 90 days were similar in the two groups.
CONCLUSIONS: Among adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality at 90 days and the number of clinically important events were similar in those assigned to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark and others; SUP-ICU ClinicalTrials.gov number, NCT02467621 .).
参考来源
- Krag M, Marker S, Perner A, et al. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. N Engl J Med. 2018. PMID: 30354950. doi:10.1056/NEJMoa1714919
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。